Straits Times Index
3,265.95 +1.42 (+0.04%) S&P 500
5,201.38 +13.71 (+0.26%) Dow
39,224.12 +167.73 (+0.43%) Nasdaq
16,334.70 +31.94 (+0.20%) Bitcoin USD
62,086.91 -125.79 (-0.20%) CMC Crypto 200
1,339.48 +39.39 (+3.03%)
Allarity Therapeutics, Inc. (ALLR)
- Zacks
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
Allarity Therapeutics, Inc. (ALLR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limited Number of Warrants Convertible at $20 Per Share Remain - Company Has Paid Off All Bridge Notes in Full Boston (May 7, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, tod
- GlobeNewswire
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
- Stockholders’ equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq’s formal confirmation of compliance with equity requirements under the exchange’s Rule 5550(b)(1). - Company will submit a request to the SEC to withdraw Form S-1 Boston (May 6, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that its st
